

DUOGLOBE: One-year Outcomes in a Real-World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease


David G Standaert, MD, PhD¹; Jason Aldred, MD²; Marieta Anca-Herschkovitsch, MD³; Paul Bourgeois, MD⁴; Esther Cubo, MD, PhD⁵; Thomas L Davis, MD⁶; Robert Iansek, BMedSci, MBBS, PhD, FRACP, OAM⁷; Norbert Kovács, MD, DSc⁸; Francesco E. Pontieri, MD⁹; Mustafa S Siddiqui, MD¹⁰; Mihaela Simu, MD¹¹; Lars Bergmann, MD¹²; Pavnit Kukreja, PharmD¹²; Weining Z Robieson, PhD¹²; K Ray Chaudhuri, MD, DSc¹³

Affiliations:

¹University of Alabama at Birmingham, Birmingham, AL, USA; ²Selkirk Neurology, Spokane, WA, USA; ³Edith Wolfson Medical Center, Holon, Israel; ⁴Department of Neurology AZ Groeninge, Kortrijk, Belgium; ⁵Neurology Department, Hospital Universitario Burgos, Burgos, Spain; ⁶Vanderbilt University Medical Center, Nashville, TN, USA; ⁷Kingston Centre, Monash Health, Melbourne, Victoria, Australia; ⁸University of Pécs, Pécs, Hungary; ⁹Sapienza University of Rome, Rome, Italy; ¹⁰Wake Forest School of Medicine, Winston Salem, NC, USA; ¹¹Victor Babes University of Medicine and Pharmacy, Timisoara, Romania; ¹²AbbVie Inc., North Chicago, IL, USA; ¹³Parkinson's Foundation Centre of Excellence, King's College Hospital, and King's College Institute of Psychiatry, Psychology & Neuroscience, London, UK

Supplemental Figures

Supplemental Figure 1. Study schematic.




^aApproximately 14 days or as recommended by the physician according to local reimbursement guidelines.

^bEffectiveness data only for patients with prior NJ treatment phase.


LCIG = levodopa-carbidopa intestinal gel; M = month; NJ = nasojejunal; PD = Parkinson's disease; PEG-J = percutaneous endoscopic gastrostomy with jejunal extension tube.

Supplemental Figure 2. Mean (SE) change from baseline in "Off" time by (A) age, (B) sex, and (C) disease duration at indicated timepoints.




BL mean \pm SE "Off" time: < 65 years (n = 40; 5.6 ± 2.9) and \geq 65 years (n = 85; 6.1 ± 3.4). Comparison between groups repeated measures model: $P = .467$.

B. Sex



BL mean \pm SE "Off" time: male (n = 104; 5.9 ± 3.5) and female (n = 60; 6.2 ± 3.2). Comparison between groups repeated measures model: $P = .379$.

C. PD Duration




BL mean \pm SE "Off" time: < 10 years (n = 78; 6.0 ± 3.6) and ≥ 10 years (n = 86; 6.0 ± 3.2). Comparison between groups repeated measures model: $P = .891$.

P values indicate significant difference compared with baseline using repeated measures model that includes country visit baseline subgroup, the baseline*visit, and the subgroup*visit interaction: $P \leq .001$ (***). BL = baseline; LCIG = levodopa-carbidopa intestinal gel; M = month.


Supplemental Figure 3. Motor and non-motor symptoms in patients treated with LCIG stratified by baseline H&Y score.

A. "Off" time




BL mean ± SD "Off" time: H&Y < 3 (n = 49; 5.6 ± 3.6) and H&Y ≥ 3 (n = 113; 6.2 ± 3.3).

B. Dyskinesia




BL mean ± SD UDysRS total score: H&Y < 3 (n = 53; 32.5 ± 16.6) and H&Y ≥ 3 (n = 98; 34.4 ± 23.4).

C. Axial symptoms




BL mean \pm SD axial symptoms score: H&Y < 3 (n = 54; 7.8 ± 4.1) and H&Y \geq 3 (n = 114; 14.3 ± 6.4).

D. NMSS total score



BL mean \pm SD NMSS total score: H&Y < 3 (n = 51; 81.3 ± 49.6) and H&Y \geq 3 (n = 110; 91.3 ± 52.1).


E. HR-QoL




BL mean \pm SD PDQ-8 summary index: H&Y < 3 (n = 53; 41.0 \pm 17.6) and H&Y \geq 3 (n = 116; 47.0 \pm 18.2).

Axial symptom scores are the sum of items 18, 22, 27-30 on UPDRS part III. *P* values indicate significant difference compared with baseline using: $P \leq .001$ (***). BL = baseline; D = day; H&Y = Hoehn and Yahr; HR-QoL = health-related quality of life; LCIG = levodopa-carbidopa intestinal gel; M = month; NMSS = Non-Motor Symptom Scale; PDQ-8 = 8-item Parkinson's Disease Questionnaire; UDysRS = Unified Dyskinesia Rating Scale; UPDRS = Unified Parkinson's Disease Rating Scale.


Supplemental Figure 4. Mean (SE) change in PDQ-8 summary index scores by (A) age, (B) sex, and (C) disease duration at indicated timepoints.



BL mean \pm SE PDQ-8 summary index: < 65 years (n = 40; 49.1 \pm 17.2) and \geq 65 years (n = 89; 44.0 \pm 18.3). Comparison between groups repeated measures model: $P = .745$.



BL mean \pm SE PDQ-8 summary index: male (n = 108; 45.1 \pm 17.8) and female (n = 63; 45.1 \pm 18.7). Comparison between groups repeated measures model: $P = .829$.



BL mean \pm SE PDQ-8 summary index: < 10 years (n = 82; 43.9 ± 19.3) and ≥ 10 years (n = 88; 46.1 ± 17.1). Comparison between groups repeated measures model: $P = .257$.

P values indicate significant difference compared with baseline using repeated measures model that includes country visit baseline subgroup, the baseline*visit, and the subgroup*visit interaction: $P \leq .001$ (***), $P \leq .01$ (**), and $P \leq .05$ (*). BL = baseline; D = day; LCIG = levodopa-carbidopa intestinal gel; M = month; PDQ-8 = 8-item Parkinson's Disease Questionnaire; SE = standard error.